METIDINE 75

  • Therapeutic Category
    • ANTIULCER DRUGS
    • GASTROINTESTINAL DRUGS
  • Pharmaceutical Form : Film Coated Tablets
  • Composition : Ranitidine 75 mg / Ctd. Tab
  • Active Substance : Ranitidine

*INDICATIONS:

The stomach contains hydrochloric acid which helps to digest food. Sometimes the stomach produces too much acid. This excess acid can lead to the conditions known as heartburn and dyspepsia (acid indigestion).

METIDINE 75 mg is indicated for the short-term relief of the symptoms of heartburn, excess acid and dyspepsia.

*CONTRAINDICATIONS:

METIDINE 75 mg is contraindicated for patients known to have hypersensitivity to ranitidine or to any ingredient in the formulation and for patients who suffer from porphyria.

*SIDE EFFECTS:

POSSIBLE SIDE EFFECTS:

  • Allergic reaction: sudden wheeziness and chest pain or tightness, swelling of eyelids, face, lips, mouth or tongue, lumpy skin rash or “hives” anywhere on the body, unexplained fever, feeling faint, especially on standing up.
  • Severe stomach pain, this may be a sign of something called “pancreatitis”.
  • Slow or irregular heartbeat.
  • Kidney problems (symptoms may include changes in the amount of urine passed and its colour, nausea, vomiting, confusion, fever and rash).

RARE SIDE EFFECTS: changes in tests which measure the function of the liver.

*WARNINGS & PRECAUTIONS:

This medicine should be given with caution:

  • In middle aged or older people who have acid indigestion symptoms for the first time or symptoms that have recently changed.
  • In patients having peptic ulcer (“stomach” or “duodenal”).
  • If there is unintended weight loss associated with dyspepsia.
  • In patients with kidney or liver problems.
  • If the patients suffer from long-term lung disease, diabetes is over 65 years or are unable to resist infection as they may be at increased risk of getting a serious chest infection (pneumonia); symptoms include fever, cough and breathlessness.
  • The patients have other illness or under regular medical supervision.

*DRUG INTERACTIONS:

Patients should tell their pharmacist or doctor before taking METIDINE 75 mg tablets – especially if they are taking:

  • Medicines to prevent blood clotting such as warfarin.
  • Pain-relievers of the class known as non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen.
  • Medicines such as triazolam and midazolam (anxiety), glipizide (oral antidiabetic), ketoconazole (antifungal agent), atazanavir and delaviridine (antiviral agents) and gefitnib (anticancer agent).

*PREGNANCY & LACTATION:

Pregnancy: The safety of METIDINE 75 mg in the treatment of conditions where a controlled reduction of gastric secretion is required during pregnancy has not been established. Reproduction studies performed in rats and rabbits have revealed no evidence of ranitidine induced impaired fertility or harm to the fetus. Ranitidine crosses the placenta.

Nevertheless, if the administration of METIDINE 75 mg is considered to be necessary, its use requires that the potential benefits be weighed against possible hazards to the patient and to the fetus.

Lactation: ranitidine is secreted in breast milk in lactating mothers but the clinical significance of this has not been fully evaluated. Like other drugs, METIDINE 75 mg should only be used during nursing if considered essential.

*DRIVING AND USING MACHINES:

METIDINE 75 mg has not been shown to affect the ability to drive or operate machinery.

*DOSAGE AND ADMINISTRATION:

Do not exceed the recommended dose.

Adults (including the elderly) and children 16 years of age and older:

One METIDINE 75 mg tablet should be swallowed whole, with a drink of water, as soon as symptoms appear, at any time of the day or night.

One or two tablets per day are usually sufficient.

No more than two tablets in 24 hours should be taken.

METIDINE 75 mg tablets should not be taken for more than 14 consecutive days without consulting the doctor or the pharmacist.

Children under 16 years:

It should not be given to children under 16 years of age.

*OVERDOSAGE:

There is no experience to date with deliberate overdosage. The usual measures are to remove unabsorbed drug from the gastrointestinal tract (including activated charcoal or syrup of ipecac), clinical monitoring and supportive therapy should be employed.

*HOW SUPPLIED: Box of 10- 20 film coated tablets.

 *STORAGE: Store in cool and dry place below 25°C.

*OTHER INFORMATION:

A number of factors may contribute towards people suffering heartburn, excess stomach acid and dyspepsia (acid indigestion): overeating, poor diet (too much fatty food), being overweight, lack of exercise, smoking and excessive alcohol intake.

If at all possible it is best to moderate your lifestyle where each of these factors is concerned to ensure you have the best possible chance of avoiding heartburn, excess stomach acid and dyspepsia.